Table 1. Patient characteristics, by sex and for the whole cohort.
| Total | Female | Male | p-value | |
|---|---|---|---|---|
| N | 22,629 | 11,411 (50.43%) | 11,218 (49.57%) | |
| Age | <0.001 | |||
| < 65 | 2,132 (9.42%) | 799 (7.00%) | 1,333 (11.88%) | |
| 65–74 | 5,589 (24.70%) | 2,421 (21.22%) | 3,168 (28.24%) | |
| ≥75 | 14,908 (65.88%) | 8,191 (71.78%) | 6,717 (59.88%) | |
| Country | <0.001 | |||
| ESP | 21,163 (93.52%) | 10,766 (94.35%) | 10,397 (92.68%) | |
| EUR | 686 (3.03%) | 260 (2.28%) | 426 (3.80%) | |
| NON-EUR | 272 (1.20%) | 136 (1.19%) | 136 (1.21%) | |
| DES | 508 (2.24%) | 249 (2.18%) | 259 (2.31%) | |
| Income | <0.001 | |||
| 0–18.000 | 19,181 (84.76%) | 10,182 (89.23%) | 8,999 (80.22%) | |
| > 18.000 | 3,448 (15.24%) | 1,229 (10.77%) | 2,219 (19.78%) | |
| Risk of social exclusion | 1,035 (4.57%) | 724 (6.34%) | 311 (2.77%) | <0.001 |
| Diagnosis | <0.001 | |||
| Atrial fibrillation | 21,624 (95.56%) | 11,030 (96.66%) | 10,594 (94.44%) | |
| Flutter | 1,005 (4.44%) | 381 (3.34%) | 624 (5.56%) | |
| Time since Therapy Initiation | 0.703 | |||
| 1–3 Years | 5,411 (23.91%) | 2,739 (24.00%) | 2,672 (23.82%) | |
| 3–6 Years | 6,611 (29.21%) | 3,305 (28.96%) | 3,306 (29.47%) | |
| > 6 Years | 10,607 (46.87%) | 5,367 (47.03%) | 5,240 (46.71%) | |
| Comorbidities | ||||
| Congestive heart failure | 4,759 (21.03%) | 2,693 (23.60%) | 2,066 (18.42%) | <0.001 |
| Hypertension | 18,817 (83.15%) | 9,677 (84.80%) | 9,140 (81.48%) | <0.001 |
| Diabetes | 8,905 (39.35%) | 4,342 (38.05%) | 4,563 (40.68%) | <0.001 |
| Liver disease | 2,095 (9.26%) | 1,017 (8.91%) | 1,078 (9.61%) | 0.070 |
| Renal disease | 3,684 (16.28%) | 1,879 (16.47%) | 1,805 (16.09%) | 0.443 |
| Previous ischemic stroke or TIA | 3,241 (14.32%) | 1,664 (14.58%) | 1,577 (14.06%) | 0.260 |
| Thromboembolism | 1,609 (7.11%) | 974 (8.54%) | 635 (5.66%) | <0.001 |
| Hemorrhagic stroke | 160 (0.71%) | 77 (0.67%) | 83 (0.74%) | 0.559 |
| Gastrointestinal bleeding | 1,644 (7.27%) | 767 (6.72%) | 877 (7.82%) | 0.001 |
| Other bleeding | 7,596 (33.57%) | 4,009 (35.13%) | 3,587 (31.98%) | <0.001 |
| Vascular disease | 4,191 (18.52%) | 1,636 (14.34%) | 2,555 (22.78%) | <0.001 |
| Dementia | 1,916 (8.47%) | 1,156 (10.13%) | 760 (6.77%) | <0.001 |
| Depression | 3,403 (15.04%) | 2,460 (21.56%) | 943 (8.41%) | <0.001 |
| Cancer | 3,878 (17.14%) | 1,570 (13.76%) | 2,308 (20.57%) | <0.001 |
| Alcohol | 189 (0.84%) | 12 (0.11%) | 177 (1.58%) | <0.001 |
| Healthcare utilisation (mean, SD) | ||||
| Hospitalizations | 0.54 (1.16) | 0.50 (1.14) | 0.56 (1.18) | <0.001 |
| ED visits | 1.00 (2.00) | 1.06 (2.08) | 0.94 (1.91) | <0.001 |
| Outpatients visits | 12.13 (7.66) | 12.84 (7.86) | 11.40 (7.38) | <0.001 |
| Specialist visits | 3.22 (4.64) | 3.09 (4.57) | 3.34 (4.71) | <0.001 |
| Cardiology visits | 0.83 (1.18) | 0.79 (1.13) | 0.88 (1.23) | <0.001 |
| Neurologic visits | 0.17 (0.60) | 0.17 (0.60) | 0.16 (0.59) | 0.367 |
| Mental Health visits | 0.11 (0.89) | 0.14 (0.93) | 0.08 (0.86) | <0.001 |
| Social care visits | 0.11 (0.74) | 0.12 (0.80) | 0.09 (0.67) | 0.004 |
| Medication use | ||||
| NSAID | 2,328 (10.29%) | 1,202 (10.53%) | 1,126 (10.04%) | 0.219 |
| Antiplatelet | 1,903 (8.41%) | 593 (5.20%) | 1,310 (11.68%) | <0.001 |
| Scores | ||||
| CHADS2 score ≥2 | 17,495 (77.31%) | 9,155 (80.23%) | 8,340 (74.34%) | <0.001 |
| CHA2DS2-VASC score ≥ 2 | 21,567 (95.31%) | 11,231 (98.42%) | 10,336 (92.14%) | <0.001 |
| HAS-BLED ≥2 | 22,238 (98.27%) | 11,244 (98.54%) | 10,994 (98.00%) | 0.002 |
| HAS-BLED ≥3 | 19,707 (87.09%) | 10,170 (89.12%) | 9,537 (85.02%) | <0.001 |
ESP: Spain; EUR: European; NON-EUR: Non-european; DES: Unknown; TIA: transient ischemic attack; ED: emergency department; NSAID: nonsteroidal anti-inflammatory drug.